Demonstrated efficacy profile1

Adult Patients

99% (152/154) of adults achieved treatment success*1

<14 minutes to treatment success*

*Two randomized, blinded, multicenter, 2-way crossover, comparative efficacy and safety trials. Adult patients aged 18 to 74 years with type 1 diabetes were in a state of insulin-induced severe hypoglycemia (plasma glucose <50 mg/dL). Treatment success was defined as plasma glucose >70 mg/dL or an increase of ≥20 mg/dL within 30 minutes of administration. Of the 161 enrolled patients, 154 received an injection of Gvoke 1 mg/0.2 mL and 157 received an injection of glucagon emergency kit 1 mg; 152 subjects received both products. The comparison between groups met the pre-specified noninferiority margin.

Reference: 1. Gvoke [prescribing information]. Chicago, IL: Xeris Pharmaceuticals, Inc.

100% (30/30) of pediatric patients experienced treatment success†1

Average change in plasma glucose at 30 minutes
2 to <6 years
(0.5 mg/0.1 mL dose)
6 to <12 years
(0.5 mg/0.1 mL dose)
12 to <18 years
(0.5 mg/0.1 mL dose)
12 to <18 years
(1 mg/0.2 mL dose)
+81 mg/dL +84 mg/dL +53 mg/dL +55 mg/dL

†Thirty-one pediatric patients with type 1 diabetes mellitus were enrolled in a sequential efficacy and safety trial. Patients were administered insulin to lower plasma glucose levels to <80 mg/dL. Treatment success was defined as achieving a prespecified target glucose increase of >25 mg/dL. Patients 2 to <12 years were administered Gvoke
0.5 mg /0.1 mL; patients 12 to <18 years were administered Gvoke 0.5 mg/0.1 mL or Gvoke 1 mg/0.2 mL.

Reference: 1. Gvoke [prescribing information]. Chicago, IL: Xeris Pharmaceuticals, Inc.

99% (152/154) of adults achieved treatment success*1

<14 minutes to treatment success*

*Two randomized, blinded, multicenter, 2-way crossover, comparative efficacy and safety studies. Adult patients aged 18 to 74 years with type 1 diabetes were in a state of insulin-induced severe hypoglycemia (plasma glucose <50 mg/dL). Treatment success was defined as plasma glucose >70 mg/dL or an increase of ≥20 mg/dL within 30 minutes of administration. Of the 161 enrolled patients, 154 received an injection of Gvoke 1 mg/0.2 mL and 157 received an injection of traditional glucagon emergency kit 1 mg; 152 subjects received both products. The comparison between groups met the pre-specified noninferiority margin.

Pediatric Patients

100% (30/30) of pediatric patients experienced treatment success†1

Average change in
plasma glucose at
30 minutes
+81 mg/dL

2 to <6 years
(0.5 mg/0.1 mL dose)

+84 mg/dL

6 to <12 years
(0.5 mg/0.1 mL dose)

+53 mg/dL

12 to <18 years
(0.5 mg/0.1 mL dose)

+55 mg/dL

12 to <18 years
(1 mg/0.2 mL dose)

†Thirty-one pediatric patients with type 1 diabetes mellitus were enrolled in a sequential efficacy and safety trial. Patients were administered insulin to lower plasma glucose levels to <80 mg/dL. Treatment success was defined as achieving a prespecified target glucose increase of >25 mg/dL. Patients 2 to <12 years were administered Gvoke 0.5 mg/0.1 mL; patients 12 to <18 years were administered Gvoke 0.5 mg/0.1 mL or Gvoke 1 mg/0.2 mL.

Reference: 1. Gvoke [prescribing information]. Chicago, IL: Xeris Pharmaceuticals, Inc.